Cargando…
Mature dendritic cells enriched in immunoregulatory molecules (mregDCs): A novel population in the tumour microenvironment and immunotherapy target
BACKGROUND: Dendritic cells (DCs) mediate divergent immune effects by activating T cells or negatively regulating the immune response to promote immune tolerance. They perform specific functions determined by their tissue distribution and maturation state. Traditionally, immature and semimature DCs...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9937888/ https://www.ncbi.nlm.nih.gov/pubmed/36808888 http://dx.doi.org/10.1002/ctm2.1199 |
_version_ | 1784890524280291328 |
---|---|
author | Li, Jiaxin Zhou, Jun Huang, Huanhuan Jiang, Jiahuan Zhang, Ting Ni, Chao |
author_facet | Li, Jiaxin Zhou, Jun Huang, Huanhuan Jiang, Jiahuan Zhang, Ting Ni, Chao |
author_sort | Li, Jiaxin |
collection | PubMed |
description | BACKGROUND: Dendritic cells (DCs) mediate divergent immune effects by activating T cells or negatively regulating the immune response to promote immune tolerance. They perform specific functions determined by their tissue distribution and maturation state. Traditionally, immature and semimature DCs were described to have immunosuppressive effects, leading to immune tolerance. Nonetheless, recent research has demonstrated that mature DCs can also suppress the immune response under certain circumstances. MAIN BODY: Mature DCs enriched in immunoregulatory molecules (mregDCs) have emerged as a regulatory module across species and tumour types. Indeed, the distinct roles of mregDCs in tumour immunotherapy have sparked the interest of researchers in the field of single‐cell omics. In particular, these regulatory cells were found to be associated with a positive response to immunotherapy and a favourable prognosis. CONCLUSION: Here, we provide a general overview of the latest and most notable advances and recent findings regarding the basic features and complex roles of mregDCs in nonmalignant diseases and the tumour microenvironment. We also emphasise the important clinical implications of mregDCs in tumours. |
format | Online Article Text |
id | pubmed-9937888 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99378882023-02-19 Mature dendritic cells enriched in immunoregulatory molecules (mregDCs): A novel population in the tumour microenvironment and immunotherapy target Li, Jiaxin Zhou, Jun Huang, Huanhuan Jiang, Jiahuan Zhang, Ting Ni, Chao Clin Transl Med Reviews BACKGROUND: Dendritic cells (DCs) mediate divergent immune effects by activating T cells or negatively regulating the immune response to promote immune tolerance. They perform specific functions determined by their tissue distribution and maturation state. Traditionally, immature and semimature DCs were described to have immunosuppressive effects, leading to immune tolerance. Nonetheless, recent research has demonstrated that mature DCs can also suppress the immune response under certain circumstances. MAIN BODY: Mature DCs enriched in immunoregulatory molecules (mregDCs) have emerged as a regulatory module across species and tumour types. Indeed, the distinct roles of mregDCs in tumour immunotherapy have sparked the interest of researchers in the field of single‐cell omics. In particular, these regulatory cells were found to be associated with a positive response to immunotherapy and a favourable prognosis. CONCLUSION: Here, we provide a general overview of the latest and most notable advances and recent findings regarding the basic features and complex roles of mregDCs in nonmalignant diseases and the tumour microenvironment. We also emphasise the important clinical implications of mregDCs in tumours. John Wiley and Sons Inc. 2023-02-17 /pmc/articles/PMC9937888/ /pubmed/36808888 http://dx.doi.org/10.1002/ctm2.1199 Text en © 2023 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Reviews Li, Jiaxin Zhou, Jun Huang, Huanhuan Jiang, Jiahuan Zhang, Ting Ni, Chao Mature dendritic cells enriched in immunoregulatory molecules (mregDCs): A novel population in the tumour microenvironment and immunotherapy target |
title | Mature dendritic cells enriched in immunoregulatory molecules (mregDCs): A novel population in the tumour microenvironment and immunotherapy target |
title_full | Mature dendritic cells enriched in immunoregulatory molecules (mregDCs): A novel population in the tumour microenvironment and immunotherapy target |
title_fullStr | Mature dendritic cells enriched in immunoregulatory molecules (mregDCs): A novel population in the tumour microenvironment and immunotherapy target |
title_full_unstemmed | Mature dendritic cells enriched in immunoregulatory molecules (mregDCs): A novel population in the tumour microenvironment and immunotherapy target |
title_short | Mature dendritic cells enriched in immunoregulatory molecules (mregDCs): A novel population in the tumour microenvironment and immunotherapy target |
title_sort | mature dendritic cells enriched in immunoregulatory molecules (mregdcs): a novel population in the tumour microenvironment and immunotherapy target |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9937888/ https://www.ncbi.nlm.nih.gov/pubmed/36808888 http://dx.doi.org/10.1002/ctm2.1199 |
work_keys_str_mv | AT lijiaxin maturedendriticcellsenrichedinimmunoregulatorymoleculesmregdcsanovelpopulationinthetumourmicroenvironmentandimmunotherapytarget AT zhoujun maturedendriticcellsenrichedinimmunoregulatorymoleculesmregdcsanovelpopulationinthetumourmicroenvironmentandimmunotherapytarget AT huanghuanhuan maturedendriticcellsenrichedinimmunoregulatorymoleculesmregdcsanovelpopulationinthetumourmicroenvironmentandimmunotherapytarget AT jiangjiahuan maturedendriticcellsenrichedinimmunoregulatorymoleculesmregdcsanovelpopulationinthetumourmicroenvironmentandimmunotherapytarget AT zhangting maturedendriticcellsenrichedinimmunoregulatorymoleculesmregdcsanovelpopulationinthetumourmicroenvironmentandimmunotherapytarget AT nichao maturedendriticcellsenrichedinimmunoregulatorymoleculesmregdcsanovelpopulationinthetumourmicroenvironmentandimmunotherapytarget |